(Démêler l¹écheveau des réductions de prix : un guide des prix pour l¹achat
des ARV pour les PED (MSF)
Ce document donne un aperçu complet des prix des médicaments
antirétroviraux offerts par les sociétés pharmaceutiques effectuant des
recherches et par certains fabricants de produits génériques des pays à
revenu faible et intermédiaire.
en anglais seulement.CB)
Untangling the Web of Antiretroviral Price Reductions: 16th Edition
http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reduct
ions-16th-edition
With nearly 10 million people now receiving treatment for HIV and
another 26 million eligible to receive it the price of antiretroviral
(ARV) drugs to put people on treatment remains a critical one.
The 16th edition of Untangling the Web finds that although the price of
first- and second-line ARVs have come down thanks to increased generic
competition, third-line or salvage regimens remain exorbitantly priced,
with middle-income countries such as Armenia paying more than US$13,000
per person per year for raltegravir, just one of the three or four drugs
needed in a third-line cocktail.
Patents remain a barrier on newer drugs and in middle-income countries,
and will need to be overcome to ensure future access to them.
AIDS_Report_UTW16_ENG_2013.pdf
<http://www.msfaccess.org/sites/default/files/AIDS_Report_UTW16_ENG_2013.pd